Latest News
Opendoor Stock Climbs 27% in Two Days as Earnings Season Nears
Opendoor shares surged 27% over two days, with trading volume reaching 26.9% of outstanding shares. Investors focus on upcoming earnings as housing market challenges persist.
Intuitive Surgical Stock Dips on Slower H2 Growth Outlook Despite Q2 Beat
Intuitive Surgical shares dropped 11.3% premarket as the company's outlook for slower second-half da Vinci procedure growth overshadowed a strong Q2 earnings beat.
Netflix Stock Plunges 9.6% on Weak Forecast, $30B Value Wiped Out
Netflix shares tumbled 9.6% in premarket trading Friday after Q3 revenue guidance fell 1.1% short of expectations, wiping out $30 billion in market value.
Nu Holdings' Regional Chief Faces Valuation Hurdle as Mexico Expansion Accelerates
Nu Holdings (NU) appoints Livia Chanes as regional head, facing valuation pressure with a P/E of 21.3, as it seeks growth beyond Brazil in Mexico and Colombia.
NJ Transit Secures $302M State Boost as Fare Revenue Stays Flat
NJ Transit approved a $3.5B operating budget with state direct aid rising 31% to $302M, while fare revenue holds at $980M, underscoring fiscal challenges.
American Airlines Faces Valuation Pressure Ahead of Q2 Earnings Report
American Airlines stock trades at a steep valuation multiple compared to peers as it prepares to report Q2 earnings on July 23, with profit conversion and fuel costs in focus.
ASX 200 Closes Lower as Materials Slide Offsets Broad Gains
The S&P/ASX 200 fell 0.50% to 8,796.7 on Friday, dragged by a 2.91% decline in materials, while seven other sectors gained. BHP, Rio Tinto, and Fortescue led the losses.
Nifty 50 Hits New High as Five Stocks Drive Two-Thirds of Gains
India's Nifty 50 advanced 1.09% to 24,334.25, driven by five major stocks that accounted for 66% of the gain, while midcap and smallcap indices declined.
Vodafone Shares Jump as Niel's Vega Boosts Voting Stake to Near 20%
Vodafone shares climbed 3.2% after Xavier Niel's Vega raised its voting stake to 19.87%, just below the 20% threshold. Vega reiterated it has no plans to make an offer, viewing the holding as a long-term strategic investment.
GSK Plummets After Failed Cough Drug Trial Wipes Out £2.36B
GSK shares fell 3% after a phase III trial failure for its chronic cough drug camlipixant erased £2.36 billion in market value, more than the cost of acquiring BELLUS.
FTSE 100 Shields Against Tech Rout; Burberry Dips on Travel Caution
The FTSE 100 opened down 0.25% but outperformed as its low tech weighting cushioned the impact of a global chip selloff. Burberry fell 5.2% despite 5% sales growth, with CFO citing tourism effects.